Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON36355
NL-OMON36355
Completed
Phase 2

An open-label phase 2A study to investigate drug-drug interactions between AT1001 (migalastat hydrochloride) and agalsidase in subjects with Fabry disease. - AT1001-013 COMBO trial

Amicus Therapeutics, Inc.0 sites4 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsFabry Diseasemetabolic disease10021605

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Fabry Disease
Sponsor
Amicus Therapeutics, Inc.
Enrollment
4
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Male, diagnosed with Fabry disease and between 18 and 65 years of age, inclusive
  • •2\. Body Mass Index (BMI) between 18\-35
  • •3\. Subject initiated treatment with agalsidase at least 1 month, having received at least two infusions, before Screening Visit
  • •4\. Subject\*s dose level, dosing regimen and form (i.e., alfa or beta) of agalsidase have been stable (stable dose defined as not varying by more than ± 20%) for at least 1 month before Screening Visit
  • •5\. Subject has a estimated creatinine clearance \* 60 mL/min at Screening; creatinine clearance to be estimated using the 4\-parameter MDRD equation:
  • •eGFR (mL/min/1\.73 m2\) \<\= 186 x (Scr)\-1\.154 x (Age)\-0\.203 x (0\.742 if female) x (1\.212 if African\-American)
  • •6\. Subject agrees to use medically accepted methods of contraception during the study and for 30 days after study completion
  • •7\. Subject is willing and able to provide written informed consent

Exclusion Criteria

  • •1\. Subject has had a documented transient ischemic attack, ischemic stroke, unstable angina, or myocardial infarction within the 3 months before Screening
  • •2\. Subject has clinically significant unstable cardiac disease (e.g., cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)
  • •3\. Subject has a history of allergy or sensitivity to study drug (including excipients) or other iminosugars (e.g., miglustat, miglitol)
  • •4\. Subject requires a concomitant medication prohibited by the protocol: Glyset® (miglitol), or Zavesca® (miglustat)
  • •5\. Any investigational/experimental drug or device within 30 days of Screening
  • •6\. Subject is currently being treated with or has previously received AT1001
  • •7\. Subject has any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator that the potential subject may have an unacceptable risk by participating in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A study to find out if an investigational new drug called AT1001 can help people with Fabry disease and if it is safe for use in combination with enzyme replacement therapy (ERT).Fabry diseaseMedDRA version: 14.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2010-022709-16-GBAmicus Therapeutics, Inc.18
Active, not recruiting
Phase 1
A study to find out if an investigational new drug called AT1001 can help people with Fabry disease and if it is safe for use in combination with enzyme replacement therapy (ERT).Fabry diseaseMedDRA version: 14.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2010-022709-16-BEAmicus Therapeutics, Inc.24
Active, not recruiting
Phase 1
An open-label Phase 2 study to assess the pharmacokinetics of Accordion Pill¿ Carbidopa-Levodopa compared to immediate release carbidopa-levodopa in patients with Parkinson¿s diseaseParkinson's Disease (PD)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2018-001209-95-ITINTEC PHARMA LTD12
Withdrawn
Phase 1
A Phase I, Open Label Study to Evaluate the Drug-Drug Interaction (DDI) of ANPA-0073 and Sildenafil in Healthy Subjects
ACTRN12622000657729Avance Clinical Pty Ltd16
Completed
Not Applicable
A phase 1, open-label study to Investigate Drug-Drug Interaction (DDI) potential of Nipocalimab with coadministration of Etanercept or Hydroxychloroquine in healthy participants.
NL-OMON49934Janssen-Cilag48